What is the best month for Novo Nordisk?
Since 2001, December has been the strongest month for Novo Nordisk, averaging +16.92% and rising in 84% of 25 years. January has been the weakest, at -5.67%.
We rate the December pattern as strong and the January pattern as no clear pattern. May comes second at +4.43%. A strong month is when prices have tended to rise, not a promise that they will.
Every month, ranked
Novo Nordisk, 2001 to 2026
| Rank | Month | Average | Median | Up years | Pattern |
|---|---|---|---|---|---|
| 1 | December | +16.92% | +3.62% | 84% | strong |
| 2 | May | +4.43% | +1.95% | 65% | weak |
| 3 | February | +2.90% | +4.90% | 73% | moderate |
| 4 | November | +2.80% | +2.23% | 76% | strong |
| 5 | August | +2.76% | +1.68% | 54% | no clear pattern |
| 6 | March | +2.39% | +1.28% | 62% | weak |
| 7 | April | +1.63% | +2.29% | 73% | moderate |
| 8 | June | +0.40% | +1.67% | 54% | no clear pattern |
| 9 | October | +0.30% | +0.92% | 56% | no clear pattern |
| 10 | July | -0.94% | -1.02% | 38% | weak |
| 11 | September | -1.88% | -1.22% | 38% | moderate |
| 12 | January | -5.67% | -0.29% | 48% | no clear pattern |
Exact date ranges
Seasonal windows that held in at least 75% of years
Likely range of the hit rate 64% to 93%. 2002 to 2013: 75%, 2014 to 2025: 92%.
Likely range of the hit rate 55% to 88%. 2002 to 2013: 83%, 2014 to 2025: 67%. Weaker in recent years.
Likely range of the hit rate 59% to 91%. 2002 to 2013: 75%, 2014 to 2025: 83%.
Likely range of the hit rate 64% to 93%. 2002 to 2013: 83%, 2014 to 2025: 83%.
Why it might happen
- GLP-1 obesity and diabetes drugs, competition with Eli Lilly and US pricing policy.
- Trial results and supply capacity announcements.
Full statistics, technicals and event reactions: Novo Nordisk. How to read these numbers: guide.
Alerts for Novo Nordisk
Pick your markets. We email when something relevant moves. Free during launch.
Not investment advice. Market Seasonality publishes historical statistics, news summaries and scenario analysis for information and education. Past patterns do not guarantee future results. Nothing here is a recommendation to buy, sell or hold any asset, and scenarios describe possible paths without predicting them. See the disclaimer and methodology.